Search company, investor...

OmniSonics Medical Technologies

omnisonics.com

Founded Year

1998

Stage

Series D | Alive

Total Raised

$90.4M

Last Raised

$20M | 15 yrs ago

About OmniSonics Medical Technologies

OmniSonics was a medical device company focused on developing breakthrough products for the treatment of vascular occlusive disease.

Headquarters Location

66 Concord Street

Wilmington, Massachusetts, 01887,

United States

978-657-9980

Missing: OmniSonics Medical Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: OmniSonics Medical Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

OmniSonics Medical Technologies Patents

OmniSonics Medical Technologies has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/24/2003

3/17/2009

Surgical removal procedures, Orthopedic surgical procedures, Medical ultrasonography, Ultrasound, Plastic surgery

Grant

Application Date

2/24/2003

Grant Date

3/17/2009

Title

Related Topics

Surgical removal procedures, Orthopedic surgical procedures, Medical ultrasonography, Ultrasound, Plastic surgery

Status

Grant

OmniSonics Medical Technologies Frequently Asked Questions (FAQ)

  • When was OmniSonics Medical Technologies founded?

    OmniSonics Medical Technologies was founded in 1998.

  • Where is OmniSonics Medical Technologies's headquarters?

    OmniSonics Medical Technologies's headquarters is located at 66 Concord Street, Wilmington.

  • What is OmniSonics Medical Technologies's latest funding round?

    OmniSonics Medical Technologies's latest funding round is Series D.

  • How much did OmniSonics Medical Technologies raise?

    OmniSonics Medical Technologies raised a total of $90.4M.

  • Who are the investors of OmniSonics Medical Technologies?

    Investors of OmniSonics Medical Technologies include Canaan Partners, Domain Associates, Johnson & Johnson Innovation, New England Partners, Tekla Capital Management and 12 more.

  • Who are OmniSonics Medical Technologies's competitors?

    Competitors of OmniSonics Medical Technologies include Endologix, Torax Medical, Tryton Medical, TriVascular Technologies, Vascular Pathways and 14 more.

Compare OmniSonics Medical Technologies to Competitors

Endologix Logo
Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

R
Reva Medical

REVA Medical develops interventional medical devices that leverage the company's stent designs and biomaterials to improve the treatment of vascular disease. Its flagship product is called MOTIV, a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product is utilized for the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The company was founded in 1998 and is based in San Diego, California.

X
XTENT

Based in Menlo Park, California, Xtent Inc. is a privately held developer of next generation drugeluting stent (DES) systems designed for the treatment of real-world patients, including those with complex, multi-lesion or multi-vessel coronary and peripheral vascular disease. Although the drugeluting stent (DES) market is today dominated by large companies, the interventional cardiology field has seen many technological breakthroughs that have changed market leadership.

Endothelix Logo
Endothelix

Endothelix, Inc. is a cardiovascular device company focused on addressing inaccurate individualized prediction of cardiovascular risk and inadequate monitoring of the vascular response to treatments.

I
Intersect Partners

Intersect Partners is a California based medical devices company. The company primarily produces intragastric balloons, stent-like neurological medical devices, and associated minimally invasive drug delivery and device systems.

S
Satiety

Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.